On September 14, 2022 OncoNano Medicine, Inc. reported a presentation of data from its ongoing Phase 2 study of pegsitacianine at the World Molecular Imaging Congress (WMIC), occurring September 27 – October 1, 2022 (Press release, OncoNano Medicine, SEP 14, 2022, View Source [SID1234619550]). The presentation will be given during the Cancer: Innovations in Molecular Imaging session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the oral presentation are as follows:

Presentation Title: Detection of Residual Peritoneal Metastases following Cytoreductive Surgery, Using the pH-sensitive Micellar Imaging Agent Pegsitacianine: An Interim Review of an Ongoing Phase 2 Study

Presenter: Patrick Wagner, MD, Department of Surgical Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania

Date/Time: Thursday, September 29, 3:12 – 3:22 PM EST